Compliance & Validation — Documented
HIPAA, SOC 2 Type II
Tempus AI
AI-enabled precision medicine platform connecting multimodal real-world clinical and molecular data.
Tempus AI builds a large library of clinical and molecular data and an operating system to make that data accessible and useful. Its platform combines genomic sequencing, multimodal real-world data, and machine learning to support oncology and other therapeutic areas, powering diagnostics, clinical trial matching, and analytics for life sciences partners.
- Headquarters
- Chicago, United States
- Founded
- 2015
- Compliance
- HIPAA, SOC 2 Type II
- Deployment options
- cloud
- Website
- https://www.tempus.com
Categories
AI Use Cases
- Patient Identification & Segmentation
- Patient Recruitment & Enrollment
- Site Selection & Performance
Vendor Scorecard
93% — Complete coverage. Coverage score — how completely Atlas documents Tempus AI across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud
Pricing Transparency — Documented
Data license + platform fee
Implementation & Onboarding — Documented
1–3 months
Organization & Role Fit — Documented
Mid-Size Biotech, Large Pharma, Top 20 Pharma, Commercial, Medical Affairs, R&D Leadership, Clinical Operations
Solution Scope — Documented
Biomarker Discovery, Natural Language Processing, Real-World Evidence
Company Viability — Partially documented
Public, Founded 2015
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Clinical Trial Activity
13 registered trials where Tempus AI is the lead sponsor (8 currently recruiting). Source: ClinicalTrials.gov, verified 2026-07-29.
Phases: Phase 2 (1)
Top conditions studied: Breast Cancer, Cancer, Pancreatic Cancer, Acute Myeloid Leukaemia (AML), Aortic Valve Stenosis
- A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies (NCT07154823, recruiting)
- Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies (NCT07211178, recruiting)
- Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension (NCT06911632, recruiting)
- Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform (NCT06099665, completed)
- A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) (NCT06163534, recruiting)
Evidence & Outcomes
U.S. FDA 510(k) clearance for Tempus ECG-AF, an AI algorithm flagging elevated atrial-fibrillation risk
Tempus received 510(k) clearance from the U.S. FDA for Tempus ECG-AF, an AI-based device that helps identify patients who may be at increased risk of atrial fibrillation/flutter. Tempus described it as the first FDA clearance for an AF indication in the category known as cardiovascular machine-learning-based notification software.
press release (Tempus AI (Business Wire)) · 2024-06-26
Questions to Ask This Vendor
- How current and complete is your real-world data in our therapeutic area?
- How does your trial-matching connect to site networks?
- How do you de-identify and govern patient data?